Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1962 1
1963 1
1964 2
1965 1
1966 1
1967 2
1968 4
1969 1
1970 3
1971 5
1973 2
1974 2
1975 5
1976 4
1977 7
1978 8
1979 8
1980 11
1981 9
1982 7
1983 7
1984 9
1985 6
1986 4
1987 5
1988 11
1989 14
1990 10
1991 8
1992 9
1993 7
1994 5
1995 5
1996 8
1997 9
1998 11
1999 4
2000 7
2001 9
2002 14
2003 12
2004 11
2005 12
2006 13
2007 20
2008 19
2009 22
2010 23
2011 16
2012 10
2013 17
2014 17
2015 14
2016 15
2017 21
2018 16
2019 32
2020 33
2021 48
2022 39
2023 44
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

663 results

Results by year

Filters applied: . Clear all
Page 1
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, Türeci Ö. Sahin U, et al. Among authors: pinter a. Nature. 2020 Sep;585(7823):107-112. doi: 10.1038/s41586-020-2537-9. Epub 2020 Jul 29. Nature. 2020. PMID: 32728218 Clinical Trial.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. Among authors: pinter a. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group. Zouboulis CC, et al. Among authors: pinter a. Br J Dermatol. 2017 Nov;177(5):1401-1409. doi: 10.1111/bjd.15748. Epub 2017 Oct 30. Br J Dermatol. 2017. PMID: 28636793
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, Reich K. Eyerich K, et al. Among authors: pinter a. BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. BMJ Open. 2021. PMID: 34518264 Free PMC article.
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkämper T, Schuster C, Puig L. Lynde C, et al. Among authors: pinter a. Adv Ther. 2023 Mar;40(3):869-886. doi: 10.1007/s12325-022-02379-9. Epub 2022 Dec 14. Adv Ther. 2023. PMID: 36515803 Free PMC article.
Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.
Magnolo N, Jaenicke T, Tsianakas A, Czech W, Thaçi D, Pinter A, Kerob D, Salah S, Luger TA. Magnolo N, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:18-26. doi: 10.1111/jdv.18949. Epub 2023 Apr 24. J Eur Acad Dermatol Venereol. 2023. PMID: 37092275 Clinical Trial.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. Among authors: pinter a. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Free article. Clinical Trial.
663 results